Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10 CHF | +2.99% | +5.04% | +102.02% |
Sales 2024 * | 36.98M 40.14M 36.14M | Sales 2025 * | 27.02M 29.33M 26.41M | Capitalization | 190M 206M 186M |
---|---|---|---|---|---|
Net income 2024 * | 15M 16.28M 14.66M | Net income 2025 * | 5M 5.43M 4.89M | EV / Sales 2024 * | 5.74 x |
Net Debt 2024 * | 22.05M 23.94M 21.55M | Net cash position 2025 * | 7M 7.6M 6.84M | EV / Sales 2025 * | 6.78 x |
P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
34.8
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Newron Pharmaceuticals S.p.A.
1 day | +2.99% | ||
1 week | +5.04% | ||
1 month | +20.34% | ||
3 months | +19.33% | ||
6 months | +108.33% | ||
Current year | +102.02% |
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 07-12-31 | |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Ulrich Köstlin
CHM | Chairman | 71 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 10 | +2.99% | 72,653 |
24-05-30 | 9.71 | +1.15% | 41,890 |
24-05-29 | 9.6 | -.--% | 49,142 |
24-05-28 | 9.6 | -1.13% | 44,626 |
24-05-27 | 9.71 | +2.00% | 32,109 |
Delayed Quote Swiss Exchange, May 31, 2024 at 11:30 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+102.02% | 206M | |
-2.44% | 89.87B | |
-3.95% | 37.57B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B | |
-17.89% | 7.32B |
- Stock Market
- Equities
- NWRN Stock